Document is current

Article History

Received: 29 June 2024

Revised: 26 August 2024

Accepted: 21 September 2024

First Online: 2 October 2024

Declarations

:

: M. Ilié: honoraria from AstraZeneca and MSD, and research funding from Amgen. A. Diepstra: research funding from Takeda. C. Eloy: advisory role for MSD, Leica, Diapath, Biocartis, Sakura, Mindpeak. F. Fend: research funding from Stemline; speaker honoraria from Stemline, EUSA Pharma. G. Hoefler: honoraria from AstraZeneca, Elsevier, MSD, Novartis, BioProducts. M. Hummel: honoraria for Novartis, AstraZeneca. E. Schuuring reports lectures for Bio-Rad, Seracare, Roche, Biocartis, Illumina, Lilly, Janssen Cilag (Johnson&Johnson), AstraZeneca, and Agena Bioscience; he is consultant in advisory boards for MSD/Merck, GSK, AstraZeneca, Astellas Pharma, Sysmex, Roche, Novartis, Bayer, BMS, Lilly, Amgen, Illumina, Agena Bioscience, Janssen Cilag (Johnson&Johnson), Sinnovisionlab, Diaceutics, CC Diagnostics; and received research grants from Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bio-science, BMS, Bio-Rad, Roche, Boehringer Ingelheim, CC Diagnostics, SNN/EFRO, and Abbott (all paid to UMCG account); and travel reimbursements from Bio-Rad, Abbott, Illumina, Agena Bioscience, Roche, IQNPath, and BioRAD. W. Timens: honororia to UMCG from Bristol-Myers Squibb, Merck Sharp Dohme. C. Benedikt Westphalen: has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, Janssen, Ipsen, MSD, Merck, Roche, Servier, SIRTeX, Taiho; served on advisory boards for Bayer, BMS, Celgene, Incyte, Janssen, Lily, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, Roche, has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, Taiho and research grants (institutional) from Roche; serves as faculty for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), and Arbeitsgemeinschaft internistische Onkologie (AIO), is a member of the EU Commission expert group: mission board for cancer; is a member of the forum #Zukunftsstrategie of the German government. P. Hofman: advisory role for: Sanofi, Amgen, Roche, Abbvie, BMS, AstraZeneca, Pfizer, Janssen, Pierre Fabre, ThermoFisher Scientific, Qiagen, Diaceutics, Novartis, Biodena, Biocartis, Eli Lilly; honoraria from: Sanofi, Amgen, Roche, BMS, AstraZeneca, Abbvie, Qiagen, Pfizer, Janssen, Pierre Fabre, ThermoFisher Scientific, Biodena, Diaceutics, Biocartis, Daiichi-Sankyo, Eli Lilly, Bayer, Novartis, Bayer; grant/research funding from: Amgen, Thermo-Fisher Scientific, Biodena, Roche. The remaining authors declare no conflicts of interest.